Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kim, H. S.
Right arrow Articles by Han, S. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, H. S.
Right arrow Articles by Han, S. Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 67, 52-62 (2002)
Copyright © 2002 by the Society of Toxicology


ENDOCRINE TOXICOLOGY

Evaluation of the 20-Day Pubertal Female Assay in Sprague-Dawley Rats Treated with DES, Tamoxifen, Testosterone, and Flutamide

Hyung Sik Kim, Jae-Ho Shin, Hyun Ju Moon, Tae Sung Kim, Il Hyun Kang, Ji-Hyun Seok, In Young Kim, Kui Lea Park and Soon Young Han,1

National Institute of Toxicological Research, Korea Food and Drug Administration, 5 Nokbun-dong Eunpyung-gu, Seoul 122–704, Korea

The Endocrine Disrupter Screening and Testing Advisory Committee (EDSTAC) has recommended the rodent pubertal female assay as a Tier I test to detect potential endocrine disrupters (EDs). This assay is designed to screen estrogenic activity in immature rats exposed to chemicals during sexual maturation. The aim of this study was to evaluate whether this assay can detect the EDs with effects brought about through various mechanisms. Immature Sprague-Dawley female rats (21 days of age) were dosed daily for 20 days by oral gavage (DES, tamoxifen, and flutamide) or sc injection (testosterone). The mean age at vaginal opening (VO) was 32.3 ± 0.5 days in control rats. Although VO was unaffected by DES at doses of 0.2 and 1.0 µg/kg, a high dose of DES (5.0 µg/kg) significantly advanced the age at VO to 24 days. Both tamoxifen (50 and 200 µg/kg) and flutamide (25 mg/kg) also significantly accelerated VO to 27.8 ± 0.5, 25.1 ± 0.1, and 26.1 ± 0.1, respectively. However, testosterone dose-dependently delayed VO (exposure to 1.0 mg/kg extended VO to 37.3 ± 0.8 days, and VO did not occur in 2 of 10 animals by the time of necropsy at 41 days of age). Estrous cyclicity was monitored in rats from VO to necropsy. Irregular cycles were observed in the groups treated with DES (5.0 µg/kg), tamoxifen (200 µg/kg), testosterone (1.0 mg/kg), and flutamide (25 mg/kg). High dose of DES showed a persistent estrus state throughout the entire observation period. In addition, the number of days in diestrus was increased by tamoxifen (200 µg/kg) and flutamide (25 mg/kg) treatments. Significant decreases in ovarian weight were observed in 5.0 µg/kg DES (64% of control), 25 mg/kg flutamide (76% of control), and 200 µg/kg tamoxifen (47% of control). Testosterone also significantly decreased the ovarian weights in all treatment groups. Uterine weights were also decreased significantly at high doses of tamoxifen (200 µg/kg, 39% of control) or testosterone (1.0 mg/kg, 47% of control). In hormone analysis, tamoxifen significantly increased serum E2 levels at 50 µg/kg. The mean serum levels of TSH were significantly increased in tamoxifen (10 and 50 µg/kg), testosterone (0.2 mg/kg), and flutamide (1.0 and 25 mg/kg) treatment groups compared with the control. However, serum T4 levels were significantly reduced by testosterone. Furthermore, serum T3 levels were significantly increased in DES, tamoxifen (10 and 50 µg/kg), testosterone (1.0 mg/kg), and flutamide (1.0 and 5 mg/kg). Our data demonstrate that the rodent pubertal female assay is useful for identifying potential EDs having not only estrogenic/antiestrogenic but also androgenic/antiandrogenic activities. However, further validation study is necessary to identify chemicals that operate through other action mechanisms, including steroid biosynthesis inhibitors and thyroid inhibitors. Moreover, additional data on other compounds with weak endocrine disrupting activity will be required to further characterize the sensitivity of the female pubertal assay.

Key Words: endocrine disrupters; female pubertal assay; vaginal opening; DES; tamoxifen; flutamide; testosterone; estrous cyclicity; hormone analysis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
D. Caserta, L. Maranghi, A. Mantovani, R. Marci, F. Maranghi, and M. Moscarini
Impact of endocrine disruptor chemicals in gynaecology
Hum. Reprod. Update, January 1, 2008; 14(1): 59 - 72.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
A. S. Clark, M. C. Kelton, and A. C. Whitney
Chronic Administration of Anabolic Steroids Disrupts Pubertal Onset and Estrous Cyclicity in Rats
Biol Reprod, February 1, 2003; 68(2): 465 - 471.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.